Publication: 3911

Patient-Reported Adverse Events during Neoadjuvant Therapy in a Phase 2 Borderline Resectable Pancreatic Cancer Clinical Trial (Alliance A021501)
   Google Scholar   
Citation:
Meeting Instance:
ASA 2023
Year:
2023
Type:
Abstract
Sub type:
Funding:
NCTN
Endpoint:
Secondary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Parents:
None
Children:
4016   4342  
Program:
OGC
Primary Committee:
GI
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882, UG1CA189823, U10CA180868 (NRG)  
Corr. Author:
 
Authors:
                 
Networks:
LAPS-MN026, LAPS-NY016, LAPS-TX035, METROMIN, NORTHWELL   
Study
Alliance-A021501
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords: